A Swedish study analyzed 5 years’ worth of data from over 3000 patients, 40% of whom received a molecular diagnosis.
Genome sequencing is leading to a large number of diagnoses among patients with rare diseases, says a new study, which is detailing how the method led to more than 12000 individuals with rare diseases receiving a precise diagnosis.
The findings were recently published in Genome Medicine.
The Swedish study analyzed 5 years’ worth of data from over 3000 patients. Of these patients, 40% received a molecular diagnosis. The researchers are calling their work “a major leap forward” in the pursuit of precision medicine. They note that although there are various ongoing large-scale genome sequencing studies around the world, clinical implementation often lags.
"Clinical whole genome sequencing has had huge implications for the area of rare diseases," said Anna Wedell, professor at the Department of Molecular Medicine and Surgery, Karolinska Institute, and one of the study’s corresponding authors, in a statement. "Used in the right way, targeted at each patient's specific clinical situation, new groups of patients can receive the right diagnosis and treatment in a way that hasn't been possible before."
In certain patients, genome sequencing reaped even more benefits, in that it was able to match some patients with personalized treatment. This included patients with inherited metabolic diseases, rare epilepsies, and primary immune deficiencies.
In total, the researchers discovered mutations in more than 750 genes while also uncovering 17 novel disease genes. Some of the most common causative genes were COL2A1 (n = 12; skeletal dysplasia), SCN1A (n = 4; epilepsy), and TNFRSF13B (n = 4; inborn errors of immunity).
Typically, it’s challenging to managing the millions of genetic variants that whole genome sequencing unearths in a patient. To circumvent this, the researchers’ model focuses on the variants considered relevant to an individual patient’s symptoms. The researchers note that this approach calls on doctors to decide which genetic analyses should be done first.
“If the first assessment fails to produce a result, the analysis is broadened to more gene panels until a diagnosis can be established and/or the whole genome is sequenced,” explained the researchers. “This process has also enabled the identification of several previously unknown disease genes, which presents new opportunities for in-depth exploration of pathogenic mechanisms.”
Reference
Stranneheim H, Lagerstedt-Robinson K, Magnusson M, et al. Integration of whole genome sequencing into a healthcare setting: high diagnostic rates across multiple clinical entities in 3219 rare disease patients. Genome Med. Published online March 17, 2021. doi:10.1186/s13073-021-00855-5
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More